Physician opinions on the implementation of the sign guideline for heart failure

Scottish Medical Journal

Volumn 49, Issue 1, 2004, Pages 10-13

  McKee, P ^a   Leslie, S J ^a   LeMaitre, J P ^a   Webb, D J ^a   Denvir, Martin A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Heart failure; Left venticular systolic dysfunction; SIGN guideline

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INFLUENZA VACCINE; SPIRONOLACTONE;

ARTICLE; AWARENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; MEDICAL SOCIETY; MEDICAL SPECIALIST; NATIONAL HEALTH SERVICE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; QUESTIONNAIRE; TEACHING HOSPITAL;

EID: 1542516244     PISSN: 00369330     EISSN: None     Source Type: Journal    
DOI: 10.1177/003693300404900103     Document Type: Article

References (25)

1. Stewart S, MacIntyre K, MacLeod MM, Bailey AE, Capewell S, McMurray JJ. Trends in hospitalisation for heart failure in Scotland, 1990-1996. An epidemic that has reached its peak? Eur Heart J 2001;22:209-217.
2. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail 2001;3:283-291.
3. Eccles M, Freemantle N, Mason J. North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure. Br Med J 1998;316:1369-1375.
4. Scottish Intercollegiate Guidelines Network. Diagnosis and Treatment of Heart Failure due to Left Ventricular Systolic Dysfunction. Royal College of Physicians Edinburgh. SIGN Number 35: 1999. ISBN 1 899893 71 7.
5. Hoppe UC, Erdmann E. Guidelines for the treatment of chronic heart failure. Issued by the Executive Committee of the German Society of Cardiology - Heart and Circulation Research, compiled on behalf of the Commission of Clinical Cardiology in cooperation with Pharmaceutic Commission of the German Physicians' Association. Z Kardiol 2001;90:218-237.
6. Hunt HA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration with the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001;104:2996-3007.
7. Remme WJ, Swedberg K. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail 2002;4:11-22.
8. Davie AP, McMurray JJ. ACE inhibitors and heart failure in hospital: any difference between cardiologists and general physicians? Postgrad Med J 1999;75:219-22.
9. Edep ME, Shah NB, Tateo IM, Massie BM. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 1997;30:518-26.
10. Schreiber TL, Elkhatib A, Grines CL, O'Neil WW. Cardiologist versus internist management of patients with unstable angina: treatment patterns and outcomes. J Am Coll Cardiol 1995;26:577-82.
11. McKee SP, Leslie SJ, LeMaitre JP, Webb DJ, Denvir MA. Management of chronic heart failure by cardiologist and non-cardiologist physicians. Eur J Heart Fail. 2002 (in press).
12. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
13. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-1435.
14. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Eng J Med 1996;334:1349-1355.
15. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
16. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
17. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Eng J Med 2001;344:1651-1658.
18. Berry C, McMurray JJ. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001;85:E8.
19. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators. N Eng J Med 1999;341:709-717.
20. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997;336:525-533.
21. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Eng J Med 1994;331:778-784.
22. Blue L, Lang E, McMurray JJ, Davie AP, McDonagh TA, Murdoch DR, Petrie MC, Connolly E, Norrie J, Round CE, Ford I, Morrison CE. Randomised controlled trial of specialist nurse intervention in heart failure. Br Med J 2001;323:715-718.
23. Cline CMJ, Israelsson BYA, Willenheimer RB, Broms K, Erhardt LR. Cost effective management programme for heart failure reduces hospitalisation. Heart 1998;80:442-446.
24. Smith M, Irving JB. Managing heart failure in the community; the role of the nurse specialist Health Bulletin 2001;59340-342.
25. McMurray JJ, StewartS. The Burden of Heart Failure. Eur Heart J 02;4:D50-58